Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Using Indoor Air Filtration to Slow Atherothrombosis Progression in Adults With Ischemic Heart Disease History

NCT: NCT05867381 · RECRUITING

NCT IDNCT05867381
StatusRECRUITING
Start Date2023-07-11
Completion2028-06-30
SponsorUniversity of Southern California (OTHER)
First posted
Last updated

Brief Summary

This double-blind, randomized, crossover trial aims to test the hypothesis that longer-term indoor air filtration intervention can slow atherothrombosis progression by reducing indoor fine particulate matter (PM2.5) exposure in adults with ischemic heart disease history.

Frequently Asked Questions

What is Using Indoor Air Filtration to Slow Atherothrombosis Progression in Adults With Ischemic Heart Disease History?

Using Indoor Air Filtration to Slow Atherothrombosis Progression in Adults With Ischemic Heart Disease History is a clinical trial registered under NCT05867381. Current status: RECRUITING.

What is the status of NCT05867381?

The current status of NCT05867381 (Using Indoor Air Filtration to Slow Atherothrombosis Progression in Adults With Ischemic Heart Disease History) is: RECRUITING.

When did Using Indoor Air Filtration to Slow Atherothrombosis Progression in Adults With Ischemic Heart Disease History start?

Using Indoor Air Filtration to Slow Atherothrombosis Progression in Adults With Ischemic Heart Disease History started on 2023-07-11.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑